1
|
Pasello G, Lorenzi M, Crivellaro G, Capelletto E, Butticè S, Perrone F, Tiseo M, Scotti V, Polo V, Favaretto A, Montrone M, Berardi R, Zustovich F, Toschi L, Bearz A, Milella M, Frega S, Bonanno L, Guarneri V. 21P Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00275-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
2
|
Sarzo G, Finco C, Zustovich F, Parise P, Savastano S, Degregori S, Vecchiato M, Merigliano S. Early Rupture of Subclavian Vein Catheter: A Case Report and Literature Review. J Vasc Access 2018; 5:39-46. [PMID: 16596539 DOI: 10.1177/112972980400500109] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Prolonged venous access devices (PVADs) have become indispensable in antiblastic protocols for the treatment of cancer patients, in anti-infection protocols for acquired immunodeficiency syndrome (AIDS) patients and in the management of chronic malabsorption syndromes. Using these catheters carries the risk of several complications, and some are potentially lethal, for example, cardiac embolization of catheter fragments. Rupture is a complication almost exclusive to catheters positioned percutaneously: after using this technique, device malfunction can occur due to catheter kinking after its excessively medial introduction in the subclavian vein. The early recognition of any pinch-off sign (POS) is fundamental in preventing catheter rupture that frequently follows this complication. Other factors can be involved in early rupture, for example, excessive force on a syringe used to clear a catheter that shows early signs of malfunction, or a strength defect in the materials used in the catheter construction. This report describes an early rupture case of an initially correctly positioned catheter and reviews 20 such cases in the recent literature.
Collapse
Affiliation(s)
- G Sarzo
- Department of Medical and Surgical Sciences, 3rd General Surgery Clinic, S. Antonio Hospital, University of Padova, Padova, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Pasello G, Vicario G, Gori S, Zustovich F, Bonetti A, Rosetti F, Favaretto A, Oniga F, Bria E, Toso S, Boccalon M, Oliani C, Palazzolo G, Frega S, Basso M, Pertile P, Bortolami A, Verrienti R, Scanni R, Conte P. Compliance to diagnostic and therapeutic pathways and innovative drug recommendations in advanced non-small cell lung cancer: preliminary results from the MOST study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Procopio G, Prisciandaro M, Iacovelli R, Mancini M, Fornarini G, Facchini G, Cartenì G, Napolitano M, Sternberg C, Caserta C, Bregni M, Massari F, Buti S, Biasco E, De Giorgi U, Zustovich F, Ratta R, Ortega C, Tortora G, Verzoni E. Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale M, Sava T, Prati G, Librici C, Fraccon A, Fornarini G, Maruzzo M, Leonardi F, Caffo O, Buti S. First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw334.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Lombardi G, Puppa AD, Zustovich F, Pambuku A, Farina P, Zagonel V. P17.53 * THE COMBINATION OF CARMUSTINE WAFERS AND FOTEMUSTINE IN RECURRENT GLIOBLASTOMA PATIENTS: OUR EXPERIENCE. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Pasini F, Fraccon A, Zustovich F, Sacco C, Valcamonico F, Donati D, Durante E, Sorarù M, Nicodemo M, Cengarle R, Randisi P, Ogliosi C, Bernardi D, Ciccarese C, Zanon S, Martellucci I, Falco I, Mucciarini C, Mandarà M, Santabarbara G. Metastatic Renal Cell Carcinoma (Mrcc) Treated with Targeted Therapies (Tt) in the Community Setting: an Italian Survey on 1238 Pts. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Cartei G, Colombrino E, Sanzari MC, Plebani M, Micucci M, Fiorica F, Giraldi T, Zustovich F, Cartei F. Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy. J Chemother 2012; 23:362-6. [PMID: 22233822 DOI: 10.1179/joc.2011.23.6.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Mitomycin C (MC) is used as therapy against solid tumors, also combined with other chemotherapeutic agents or radiotherapy. It may cause acute, subacute, or chronic anemia capable of modifying the results of chemo- and radiotherapy. Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy. There are few studies investigating the relationship between erythropoietin and chronic anemia.We prospectively analyzed the chronic anemia and erythropoietin in 38 patients with solid cancer. Patients were 40 to 82 years of age. MC was randomly given every 3 weeks as a single drug at 10 or 20 mg/m². When myelotoxicity occurred the next therapy cycle was delayed until recovery. RBC indices, hemolysis, erythropoietin, liver and kidney function were studied. MC cycles were 136 (3.6 ± 1.4 per pt), 32 being delayed because of myelotoxicity.Hematocrit, hemoglobin and RBC were inversely related to the cumulative dose (r = 0.70 to 0.86; p 0.03 to 0.01) of MC. Other tests remained stable. Anemia occurred almost twofold earlier in the 20 mg/m² group (p=0.049). basal erythropoietin, already lower than in age and sex watched 81 non cancerous subjects (p<0.001), decreased during MC therapy (p<0.01). For each given MC mg/m² a 0.0372 Hb mg/dl reduction occurred. Chronic anemia due to MC is accompanied by erythropoietin reduction. These results can help in designing chemoradiotherapy.
Collapse
Affiliation(s)
- G Cartei
- Oncology Section Geriatric Hosp. USL 16, Padova, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Lombardi G, Zustovich F, Zovato S, Fiore D, Cappetta A, Pastorelli D. Characteristics and management of pancreatic lesions in Von Hippel-Lindau disease: a systematic literature review. Oncol Rev 2011. [DOI: 10.4081/oncol.2009.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Von Hippel-Lindau disease is a rare autosomal dominant inherited disorder that predisposes the occurrence of cysts and various types of cancers such as hemangioblastoma, pheochromocytoma, renal cell carcinoma and more rarely pancreatic tumors. In this review, we analyze the characteristics and management of pancreatic lesions, in particular cysts and neuroendocrine tumors, in Von Hippel-Lindau disease.
Collapse
|
10
|
Lombardi G, Zustovich F, Zovato S, Fiore D, Cappetta A, Pastorelli D. Characteristics and management of pancreatic lesions in Von Hippel-Lindau disease: a systematic literature review. Oncol Rev 2011. [DOI: 10.4081/83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
11
|
Lombard! G, Zustovich F, Fiduccia P, Farina P, Puppa AD, Orvieto E, Gardiman M, Berti F, Zagonel V. 8746 POSTER Could Hypertension Be a Potential Biomarker in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Drugs? -a Retrospective Analysis. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72297-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Lombardi G, Zustovich F, Della Puppa A, Gardiman MP, Farina P, Carollo C, Landi L, Cecchin D, Bertorelle R, Berti F, Fiduccia P, D'Avella D, Zagonel V. A retrospective study analyzing the association between tumor response (TR) according to Mcdonald criteria (MC) on MRI and survival (OS) in patients (PTS) with glioblastoma (GBM) treated with antiangiogenic drugs (AD). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e12514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Zustovich F, Landi L, Lombardi G, Galli L, Porta C, Amoroso D, Fontana A, Andreuccetti M, Galli C, Falcone A, Zagonel V. Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2080] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Della Puppa A, Rossetto M, Berti F, Zustovich F, Manara R, Gardiman MP, Scienza R. Internal auditory canal metastasis. J Neurosurg Sci 2010; 54:159-162. [PMID: 21423087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Metastasis of the inner auditory canal is a really rare event. Clinically, it usually presents with rapid worsening cranial nerve palsy. Authors present a review of the literature reporting clinical features, radiological findings, intraoperative aspects of an illustrative case. A 56-year-old female patient presented with a peripheral facial nerve palsy. MRI showed two left p-fossa tumors whose one into the inner canal. Rapid worsening of facial damage despite corticosteroid treatment and the possibility to remove both tumors in the same surgical step suggested authors to operated on the patient. Intraoperatively, inner canal tumor looked totally involving the VII-VIII nerve complex so surgical extirpation was only partially feasible. Posterior wall drilling of the meatus was performed which improved facial palsy. Leptomeningeal spinal seeding occurred and spinal irradiation was performed. The case highlights the importance of maintaining a high degree of awareness of the auditory canal metastasis in patients with a previous history of malignancy who develop a rapid progressive peripheral VII nerve palsy. Furthermore, our case and literature data suggest that inner canal metastasis is a distinct entity from temporal bone and ponto-cerebellar angle metastasis on the base of the peculiarity of clinical features, prognosis, therapeutic strategies. In fact, inner canal metastases usually arise in patients apparently cured, and they imply a better prognosis even if with an higher risk of leptomeningeal seeding. Moreover, surgery rarely allows the removal of the lesion, also if symptoms relief may be achieved, as in our case.
Collapse
Affiliation(s)
- A Della Puppa
- Department of Neurosurgery, Padua University Hospital, Padua, Italy.
| | | | | | | | | | | | | |
Collapse
|
15
|
Lombardi G, Pastorelli D, Zustovich F, Farina M, Furini L, Cappetta A, Zagonel V. Factors predicting time-to-progression (TTP) and overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) treated by combination gemcitabine (G) and pegylated liposomal doxorubicin (PLD) chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14618] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Furini L, Artioli G, Lombardi G, Zustovich F, Faggioni G, Scattolin G, Carli P, Pastorelli D, Nicoletto M. P49 Chemotherapy in older women with ovarian cancer. Crit Rev Oncol Hematol 2009. [DOI: 10.1016/s1040-8428(09)70087-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
17
|
Lombardi G, Zustovich F, Carli P, Puppa AD, Rotilio A, Scienza R, Pastorelli D. 8715 Cisplatin and Temozolomide in heavily pretreated and poor performance status (PS) patients with temozolomide refractory glioblastoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71689-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
18
|
Pastorelli D, Zustovich F, Lombardi G, Zovato S, Farina M, Furini L, Faggioni G, Nicoletto M, Ceravolo R. 6620 Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in the treatment of advanced hepatocellular carcinoma (HCC). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71341-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
19
|
Affiliation(s)
- G. Lombardi
- Oncologia Medica 1 — Istituto Oncologico Veneto, IRCCS, Padova, Italy,
| | - F. Zustovich
- Oncologia Medica 1 — Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - MO Nicoletto
- Oncologia Medica 1 — Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - M. Donach
- Oncologia Medica 1 — Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - D. Pastorelli
- Oncologia Medica 1 — Istituto Oncologico Veneto, IRCCS, Padova, Italy
| |
Collapse
|
20
|
Lombardi G, Zustovich F, Zovato S, Fiore D, Cappetta A, Pastorelli D. Characteristics and management of pancreatic lesions in Von Hippel-Lindau disease: a systematic literature review. Oncol Rev 2009. [DOI: 10.1007/s12156-009-0013-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
21
|
|
22
|
Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G. Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien) 2008; 150:699-702; discussion 702-3. [PMID: 18548193 DOI: 10.1007/s00701-008-1507-z] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2007] [Accepted: 12/20/2007] [Indexed: 11/29/2022]
Abstract
Oligodendroglioma cells are detectable in the cerebro-spinal fluid in up to 14% of patients [10] and cerebellar and/or spinal cord involvement is a well known phenomenon [3]. Distant spread of oligodendroglioma is exceptional, probably due to the presence of the blood-brain barrier, the absence of lymphatic vessels and the short survival of patients. A review of the worldwide literature yielded 32 previously reported examples since 1951 to the present (Tab1e 1). This review was performed using NCBI-PubMed and "oligodendroglioma, oligodendrogliomas, metastatic, metastasis, metastases, extraneural", in different combinations, as key words and reviewing the bibliography of the consequent selected articles. New therapeutic approaches are prolonging the overall survival of patients with primitive brain tumours and in particular of those with high grade oligodendroglioma which is a chemo-sensitive disease. A longer overall survival could increase the risk of extracranial dissemination of gliomas that in the future might become a less rare clinical complication.
Collapse
Affiliation(s)
- F Zustovich
- Oncologia Medica 1, Istituto Oncologico Veneto - I.R.C.C.S., Padova, Italy.
| | | | | | | | | | | |
Collapse
|
23
|
Zustovich F, Cartei G, Dal Bianco M, De Zorzi L, Ceravolo R, Zovato S, Salmaso F, Binato S, Artioli G, Cingarlini S, Pastorelli D. A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature. Ann Oncol 2008; 17 Suppl 5:v133-6. [PMID: 16807442 DOI: 10.1093/annonc/mdj968] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- F Zustovich
- O.U.C. Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto (IOV - IRCCS ) Padua, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Della Puppa A, Zustovich F, Gardiman M, Manara R, Cecchin D, Scienza R. Haemorrhagic presentation of low-grade glioma in adults. Acta Neurochir (Wien) 2007; 149:1151-5; discussion 1155. [PMID: 17676407 DOI: 10.1007/s00701-007-1263-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2007] [Accepted: 07/10/2007] [Indexed: 10/23/2022]
Abstract
Intracranial bleeding is rare in patients with low-grade gliomas, above all in adult population. We reviewed the literature of such cases and reported another case of a haemorrhagic low-grade glioma in a 54-year-old woman presenting with a left hemiparesis. Computer tomography (CT) images showed a right basal ganglia haemorrhage with no mass effect. Vascular malformations were ruled out by angiography. Eighteen fluoro-fluoro deossiglucosio (18F-FDG) positron emission tomography (PET/CT) showed a large hypometabolic area corresponding to the lesion. We waited for patient's improvement. Late magnetic resonance images revealed a low-grade glioma at the bleeding site. Tumour was removed and histopathologic examination revealed a WHO grade II mixed glioma. The authors emphasize that this evidence has to be kept in mind since it has important therapeutic implications.
Collapse
Affiliation(s)
- A Della Puppa
- Department of Neurosurgery, Padua Hospital, Padua, Italy.
| | | | | | | | | | | |
Collapse
|
25
|
Caffo O, Sava T, Comploj E, Giampaolo M, Zustovich F, Segati R, Sacco C, Perin A, Pappagallo G, Valduga F. Docetaxel (D) and estramustine (E) as first-line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC): Final results of a multicentric phase II randomized trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15552] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15552 Background: Preclinical data showed a synergism between E and D and several studies supported an advantage in associating E and D. Nevertheless, D is considered a standard treatment for HRPC pts and the role of D+E combination remains controversial. Purpose of this study was to evaluate the activity, in terms of PSA decline (PSA↓), the safety and quality of life (QoL) of D±E in HRPC pts. Methods: Eligibility criteria included: HRPC diagnosis, hormone-refractory advanced disease (PSA progression after at least two hormonal therapy), ECOG PS < 2, adequate renal, hepatic and hematological functions, no prior chemotherapy. Pts were randomized to D 70 mg/m2 IV d1 q3w (arm A) or D 70 mg/m2 IV d1 q3w + E 280 mg/TID PO starting 1 day prior to D, for 5 consecutive days (arm B). The treatments were planned until best PSA response achievement or PSA progression. Toxicity was recorded according to NCIC criteria. Qol was assessed by self-filled questionnaires during the treatment. Results: Between 04/2003 and 09/2005, 95 pts (median age 69 years, range 48–86, median PSA 80 ng/ml, range 5–2,166 and measurable disease in 45) were randomized to arm A (49) or arm B (46). In arm A, pts received 321 cycles (median 6, range 0–28) with only 13 (4 %) delays = 7 days. In arm B, pts received 338 cycles (median 7, range 0–20) with only 16 (4.7%) delays. Grade 3–4 hematological toxicities consisted of neutropenia, 4% in arm A and 6% in B. One pt in arm B had febrile neutropenia and grade 3 diarrhea. Grade 3–4 non-hematologic toxicities were vomiting (1 pt in both arms), stomatitis (1 pt in arm A and 2 pts in B) and diarrhoea (1 pt in arm B). Two cases of stroke were reported in arm A. No treatment related death was recorded. Responses, in terms of PSA↓ >50% were: 40% in arm A and 75%in arm B with PSA normalization in 5% and 32% respectively. After a median follow-up of 17 months, 65 patients are died (31 in Arm A and 34 in Arm B). Progression free survival (biochemical) was 20 weeks in arm A and 30 in B. Conclusions: D-based regimens are active in HRPC with a manageable toxicity profile. From this preliminary data, DE combination appears promising, in terms of activity and tolerability so, front-to-front formal comparison in a phase III trial can be recommended. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Caffo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - T. Sava
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - E. Comploj
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - M. Giampaolo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - F. Zustovich
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - R. Segati
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - C. Sacco
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - A. Perin
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - G. Pappagallo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - F. Valduga
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| |
Collapse
|
26
|
Sava T, Comploj E, Fariello G, Zustovich F, Segati R, Sacco C, Perin A, Mandarà M, Cetto G, Caffo O. Predictive value of PSA halving index (PSAHI) in patients (pts) with hormone refractory prostate cancer (HPRC): Results from a randomized phase II trial with docetaxel (D) ± estramustine phopshate (E). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15548 Background: D-based chemotherapy represents the standard treatment for HRPC pts. For several years PSA has been considered as a surrogate endpoint for studies involving pts with HRPC. The possibility of predicting a clinical advantage through the biochemical response rate is controversial. The PSAHI may represent a predictive parameter more than the simple PSA trend. We retrospectively evaluated the role of PSAHI in a consecutive series of patients affected by HRPC and treated in a randomized phase II trial with D±E. Methods: 95 pts affected by HRPC were randomized to D 70 mg/m2 IV d1 q3w (arm A: 49 pts) or D 70 mg/m2 IV d1 q3w + E 280 mg/TID PO starting 1 day prior to D, for 5 consecutive days (arm B: 46 pts). The treatment continued until best PSA response achievement or PSA progression. PSAHI was calculated comparing basal value (the day before first D administration) with those reached after every cycle at 21, 42, 63 and 84 days: each median value was then correlated across all pts. Correlations were made with response, time to progression (TTP) and overall survival (OS). Results: Responses, in terms of PSA? >50% were: 40% in arm A and 75%in arm B with PSA normalization in 5% and 32% respectively. After a median follow-up of 17 months, 65 patients are died (31 in Arm A and 34 in Arm B). Progression free survival (biochemical) was 20 weeks in arm A and 30 in B. Median PSAHI was 2.1 (0.8–8.8) and resulted significantly related to response and TTP: pts with PSAHI less than 1 and more than 1 had a median TTP of 14 and 34 weeks respectively. Between the 4 PSAHI analyzed (after 21, 42, 63 and 84 day), those at 42 and, particularly, 63 day resulted statistically related to response, TTP and OS. After 3 cycles, the PSA decline (63-PSAHI) was highly predicyive of OS which was 63, 72 and 90 weeks respectively (p=0.03), for pts with PSAHI of less than 1, between 1 and 3 and more than 3. Conclusions: PSAHI seems to be highly predictive of TTP and OS. 63-PSAHI seems to be a good surrogate marker of D response and may help in discriminating pts who need to be further treated with D and those who do not. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Sava
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - E. Comploj
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - G. Fariello
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - F. Zustovich
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - R. Segati
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - C. Sacco
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - A. Perin
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - M. Mandarà
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - G. Cetto
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - O. Caffo
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| |
Collapse
|
27
|
Pastorelli D, Cartei G, Zustovich F, Zovato S, Artioli G, Ceravolo R, Nicoletto M, Binato S, Mattiazzi M. A phase II study of pegylated liposomial doxorubicin (PLD) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4585] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4585 Background: There is no gold standard pharmacological treatment for HCC not suitable for loco-regional therapy. Antracyclines have been often used for the chemotherapy of HCC with low efficacy and well known toxicity. Availability of new drugs and in particular of PLD could enhance the chance of treatment and contain side-effects. Gemcitabine is active against the most solid tumors. Patients and Methods: We enrolled 35 patients (PTS) with histological diagnosis of HCC not suitable for loco-regional treatment and adequate haematological function.; median age was 63.2 (range 44.0–77.4); male/female=29/6; PS=0 in 30 PTS, PS=1 in 4 PTS and PS=2 in 1 PT. Eighteen PTS had metastatic disease. Prior treatments were TACE in13 PTS, PEI in 9, surgery in 12, RFTA in 5 and chemotherapy in 3. Nineteen patients had Child-Pough A-B cirrhosis HBV-HCV related. PLD was administered at the dose of 30mg/m2 over a 60’ infusion every 28 days and G at the dose of 1,000mg/m2 over 30’ infusion days 1 and 8 every 28 days. Instrumental response evaluation was performed every 3 cycles and treatment was continued until disease progression or major toxicity evidence. Results: All PTS were valuable for toxicity: G1–2 toxicity was neutropenia in 5 PTS, thrombocytopenia in 7, mucositis in 3 and PPE in 3. G3–4 toxicity was neutropenia in 6 PTS and thrombocytopenia in 1. Thirty-four PTS were valuable for response with CR in 2, PR in 6, SD in 12 and PD in 14. Thirty-four PTS were valuable for TTP: median was 6.2+ months (range 1.9–31.7+). All PTS were valuable for OS: median was 8.8+ months (range 1.9–36.5+). Conclusions: The combination of PLD and G is safe and effective in treatment of HCC. No life-threatening toxicity was experienced and disease control rate was about 60%. No significant financial relationships to disclose.
Collapse
|
28
|
|
29
|
Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Valduga F, Frisinghelli M, Segati R, Sacco C, Perin A, Pappagallo G. A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4625] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4625 Background: D is presently considered a standard treatment for HRPC pts. E has shown a synergistic activity with D in vitro, however the role of D+E combination remains to be defined in the clinical practice. We attempted to evaluate the activity, in terms of PSA decline (PSA↓), the safety and quality of life (QoL) of D ± E in HRPC pts. Methods: eligibility criteria were: HRPC diagnosis, hormone-refractory advanced disease (PSA progression after at least two hormonal therapy), ECOG PS ≤ 2, adequate renal, hepatic and hematological functions. Pts were randomized to D 70 mg/m2 IV d1 q3w (arm A) or D 70 mg/m2 IV d1 q3w + E 280 mg/TID PO starting 1 day prior to D, for 5 consecutive days (arm B). The treatments were planned until best PSA response achievement or PSA progression. No anticoagulant prophylaxis was planned in ARM B pts. Qol was assessed by self-filled questionnaires during the treatment. Results: Between 04/2003 and 09/2005, 95 pts (median age 69 years, range 48–86, median PSA 80 ng/ml, range 5–2166 and measurable disease in 45) were randomized to arm A (49) or arm B (46). To date, 9 pts and 6 pts are still on treatment in arm A and B respectively. In arm A, pts received 257 cycles (median 5, range 1–14) with only 10 (3.9%) delays ≥ 7 days. In arm B, pts received 317 cycles (median 7, range 0–20) with only 15 (4.7%) delays. Median follow-up was 19.5 months. Grade 3–4 hematological toxicities consisted of neutropenia, 4% in arm A and 8% in B, anemia, 0% and 2% respectively and 1 pt with febrile neutropenia and grade 3 diarrhea (Arm B). Grade 3−4 non-hematologic toxicities were vomiting (1 pt) in arm A, stomatitis (2 pts) and vomiting (1 pt) in arm B. Two cases of stroke were reported in arm A. Responses, in terms of PSA↓ >50% were: 43% in arm A and 70% in arm B with PSA normalization in 8% and 38% respectively. Progression free survival (biochemical) was 20 weeks in arm A and 31 in B. Analysis concerning QoL outcomes is planned at the treatment completion of all pts. Conclusions: D-based regimens are active in HRPC with a low toxicity profile. From this preliminary data, DE combination appears promising, in terms of activity and tolerability so, front-to-front formal comparison in a phase III trial can be recommended. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Caffo
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - T. Sava
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - E. Comploj
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - A. Fariello
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - F. Zustovich
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - F. Valduga
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - M. Frisinghelli
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - R. Segati
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - C. Sacco
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - A. Perin
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - G. Pappagallo
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| |
Collapse
|
30
|
Zustovich F, Cartei G, Ceravolo R, Salmaso F, Zovato S, Artioli G, Cingarlini S, Binato S, Pastorelli D. Fixed infusion rate (FIR) gemcitabine (G) based treatment for advanced renal cell carcinoma (ARCC): Efficacy and toxicity data from a phase II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14632 Background: ARCC is still an untreatable disease because high dose IL2 therapy is feasible and effective only in a small percentage of patients (pts). Standard dose IL2 is palliative as well as every other treatment. G is a well tolerated agent, even in aged pts and is moderately effective in ARCC. FIR of 10 mg/m2/min increases intracellular G active metabolites and may enhance therapeutic and toxic effect. Aim of study was to evaluate the FIR-G effectiveness in ARCC. Methods: G was administered IV at 10 mg/m2/min FIR for 50 to 1250 min according to age and PS on day 1,8,15 every 28. Immunotherapy (IT) was IL2 3MU subcutaneously daily for 5 days a week or Alfa-INF 3MU three days a week, chronically given. Results: We enrolled 23 pts; 5 female; median age 59 years (29–75), all stage IV disease, all nephrectomized with histologically confirmed clear cell carcinoma; median Fhurman’s grade was 3 (1–4); median PS was 2 (0–3); 9 pts had bone mets; prior treatments: IT, mostly low doses IL2, in 12 pts; chemotherapy in 7 pts and palliative radiotherapy in 9 pts. 125 cycles (median of 5, range 1–35) were administered with a median G dose of 1050 mg/m2 over 105’. 13 Pts received IT (11 pts were IT naïve and received IL2 and 2 pts previously treated with IL2 received Alfa-INF). In the 22 pts valuable for toxicity grade 1–2/#pts was: granulocytopenia/5, anemia/2, nausea/5, vomiting/2, constipation/1, mucositis/1, fever/1, infection/1, fatigue/2, cutaneous/5, peripheral edema/4; grade 3–4 was: anemia/3, nausea/1, fatigue/3, cutaneous/1, vascular venous/1, peripheral edema/1. 26 cycles had to be delayed due to side effects. In the 22 valuable pts we reported 3 PR with a RR of 14% and 11 pts (50%) had SD. All pts were valuable for TTP with a median of 5.6 months (1–35). Data on OS are still immature with a median of 15+ (3–55+). Conclusions: FIR-G ± IT is safe and moderately effective against ARCC. Due to the small number of pts no separate analysis is possible between G ± IT or prognostic factors groups. Nevertheless our TTP and OS data are promising considering the detrimental prognostic factors in the treated population. Present work was part of studies program of, and partly supported by, AOI (Associazione Oncologia Italiana), Padova, Italy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Zustovich
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - G. Cartei
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - R. Ceravolo
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - F. Salmaso
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - S. Zovato
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - G. Artioli
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - S. Cingarlini
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - S. Binato
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| | - D. Pastorelli
- Medical Oncology 1st floor IOV- IRCCS, Padova, Italy
| |
Collapse
|
31
|
Pastorelli D, Cartei G, Zustovich F, Marchese F, Artioli G, Zovato S, Binato S, Ceravolo R, Cingarlini S, Salmaso F, Mattiazzi M, Sanavio C, Farinati F, Zanus G, Cillo U. Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol 2006; 17 Suppl 5:v153-7. [PMID: 16807446 DOI: 10.1093/annonc/mdj972] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. PATIENTS AND METHODS Clinical trials for biliary and hepatic carcinoma have been reviewed. RESULTS We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m(2) d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).
Collapse
Affiliation(s)
- D Pastorelli
- O.U.C. Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto, IOV - IRCCS, Padua, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Cartei G, Zustovich F, Murrone A, Zovato S, Binato S, Mattiazzi M, Farinati F, Zanus G, Cillo U, Pastorelli D. A phase I-II study of liposomal doxorubicin (LD) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Cartei
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - F. Zustovich
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - A. Murrone
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - S. Zovato
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - S. Binato
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - M. Mattiazzi
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - F. Farinati
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - G. Zanus
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - U. Cillo
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| | - D. Pastorelli
- Medcl Oncology ULSS16 Padova, Padova, Italy; Azienda Osp di Padova, Padova, Italy; Medcl Oncology ULSS16, Padova, Italy
| |
Collapse
|
33
|
Zustovich F, Cartei G, Ceravolo R, Salmaso F, Zovato S, Binato S, Pastorelli D. Cisplatin (C), temozolomide (T) every 21 days and concomitant thalidomide (TH) in patients (PTS) with malignant gliomas. Final results of a phase I study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Zustovich F, Cartei G, Trestin A, Palù G, Palumbo M, Barzon L, Franchin E, Mattiazzi M, Binato S, Zovato S. Analysis of topoisomerase (TOP) expression in peripheral blood mononuclear cell (PBMCs) from patients (PTS) undergoing chemotherapy (CHT) for solid tumors( ST). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Zustovich
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - G. Cartei
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - A. Trestin
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - G. Palù
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - M. Palumbo
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - L. Barzon
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - E. Franchin
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - M. Mattiazzi
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - S. Binato
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| | - S. Zovato
- IOV Padova, Padova, Italy; Depts of Histology, Microbiology, Medical Biotechnology and Pharmaceutical Sciences, University of Padova, Italy
| |
Collapse
|
35
|
Cartei G, Clocchiatti L, Sacco C, Pella N, Bearz A, Mantero J, Pastorelli D, Salmaso F, Zustovich F. Dose finding of ifosfamide administered with a chronic two-week continuous infusion. Oncology 2003; 65 Suppl 2:31-6. [PMID: 14586144 DOI: 10.1159/000073355] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PURPOSE Ifosfamide (IFO) is an active drug in several malignancies. A short-term 3- to 7-day (A) continuous infusion (c.i.) has been used in different tumor types. The 14-day c.i. (B) has been investigated in advanced breast cancer and in soft tissue sarcoma patients at a fixed daily dose. The tolerance and response rate (RR) of therapies A and B has been considered encouraging. AIM To study the 14-day c.i. IFO schedule, every 28 days, with a dose-finding approach. METHODS From January 1998 to December 2001, 34 pretreated patients with advanced malignancy and disease progression were treated with c.i. IFO (and the same dose of mesna) from 400 to 1,000 mg/m(2)/24 h for 2 consecutive weeks every 28 days. An elastomeric pumping device via an Infuse-a-Port((R)) or a Groshong((R)) catheter was used. RESULTS A total of 159 cycles were evaluable for toxicity and results. No toxic deaths occurred. Three patients (8.8%) had a severe acute allergic cutaneous reaction with various grade 3-4 toxicities requiring hospitalization and therapy was stopped at day 6 of the first cycle, 7 and 12 of the second cycle respectively. In the other 31 patients, grade 4 neutropenia occurred in 6 (19.3%) and it represented the main toxicity. There was a positive relationship between the IFO dose step and neutropenia (p = 0.001). A positive relationship was observed between the RR and the received total IFO dose (g) (p < 0.004). Twelve patients out of 31 had progressive disease (PD) (38.7%), 8 had partial remission (PR) (25.8%), and 11 maintained a steady state (35.5%). Six of the 12 patients (50%) with PD and 2 of the 8 PRs (25%) had bone metastases. CONCLUSIONS IFO c.i. is generally well tolerated, but acute untoward allergic reactions can occur. In chemotherapy-pretreated patients the recommended daily dose of continuously infused IFO for 14 days every 4 weeks is 900 mg/m(2)/day, together with mesna at the same dose schedule.
Collapse
Affiliation(s)
- G Cartei
- General Oncology, ULSS 16, Padova, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|